Pharmacovigilance Outsourcing Market Report 2026

The pharmacovigilance outsourcing market size has grown rapidly in recent years. It will grow from $7.24 billion in 2025 to $8.51 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to rising number of new drug approvals, increasing pharmacovigilance awareness among pharma companies, lack of in-house pv expertise, growing regulatory scrutiny, expansion of global clinical trials.

The pharmacovigilance outsourcing market size is expected to see rapid growth in the next few years. It will grow to $16.09 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to integration of ai and data analytics in pv processes, increasing outsourcing to cro and bpo providers, adoption of cloud-based pharmacovigilance platforms, expansion of global safety reporting requirements, growing investment in it infrastructure and technology support. Major trends in the forecast period include increasing adoption of outsourced pharmacovigilance services by pharma companies, rising regulatory compliance requirements and reporting standards, growth in automation of adr capture and case processing, expansion of knowledge management and data integration solutions, enhanced focus on risk management and quality assurance services.

The increasing number of clinical trials is anticipated to drive the growth of the pharmacovigilance outsourcing market in the coming years. Clinical trials are research studies carried out to assess the safety, effectiveness, and potential side effects of new drugs, treatments, or medical devices. The rise in clinical trials is attributed to factors such as the growing emphasis on precision medicine, the increasing prevalence of chronic diseases, supportive regulatory frameworks, and the globalization of research activities. Pharmacovigilance outsourcing plays a vital role in clinical trials by strengthening drug safety monitoring through the use of specialized expertise and resources, ensuring regulatory compliance, and improving operational efficiency. For example, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the number of industry-sponsored clinical trials initiated in the UK increased to 426 in 2023, up from 411 in 2022. Consequently, the growing number of clinical trials is contributing to the expansion of the pharmacovigilance outsourcing market.

Major companies operating in the pharmacovigilance outsourcing market are concentrating on the development of innovative solutions, such as cloud-based data lake platforms, to optimize pharmacovigilance case processing and safety data management while enhancing clinical research registries and ensuring regulatory compliance. A cloud-based data lake platform serves as a centralized repository that enables the storage and management of large volumes of raw data in its original format until required for analysis. For instance, in December 2023, Thermo Fisher Scientific Inc., a US-based biotechnology and laboratory equipment company, introduced CorEvidence, a solution designed to enhance clinical research registries. The platform streamlines pharmacovigilance case processing by integrating multiple data sources and improving the coding, classification, and reporting of adverse events. Its importance lies in delivering scalable, compliant, and auditable safety management, strengthening CorEvitas clinical research registries, and supporting long-term post-authorization safety studies across a wide range of therapeutic areas.

In November 2023, Permira Advisers LLP, a UK-based investment firm, acquired Ergomed PLC for $0.904 billion. This acquisition is intended to support Ergomed’s next phase of growth by utilizing Permira’s expertise, financial resources, and global network to expand Ergomed’s commercial, technological, and geographic reach, as well as to enable strategic acquisitions within the contract research organization and pharmacovigilance sectors. Ergomed PLC is a UK-based company that provides drug development services, including pharmacovigilance.

Major companies operating in the pharmacovigilance outsourcing market are ACCENTURE PLC, International Business Machines Corporation (IBM), Tata Consultancy Services, Capgemini SE, Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., Wipro Limited, ICON PLC, Syneos Health, Genpact limited, Parexel International Corp, Veeva Systems Inc., Medpace Holdings Inc., ProPharma Group, Pharmalex GmbH, PrimeVigilance Ltd., Veristat LLC, United BioSource LLC, Lambda Therapeutic Research, ArisGlobal, Biomapas.

North America was the largest region in the pharmacovigilance outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacovigilance outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmacovigilance outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pharmacovigilance outsourcing market by increasing costs of imported software, IT infrastructure, and analytics tools used in ADR capture, case processing, and reporting services. Service providers relying on imports are most affected, particularly in North America and Europe. While tariffs have led to higher operational costs and slowed deployment of new technologies, they have also encouraged investment in local IT solutions, promoted domestic service capabilities, and fostered innovation in automation and data integration platforms.

The pharmacovigilance outsourcing market research report is one of a series of new reports that provides pharmacovigilance outsourcing market statistics, including pharmacovigilance outsourcing industry global market size, regional shares, competitors with a pharmacovigilance outsourcing market share, detailed pharmacovigilance outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacovigilance outsourcing industry. This pharmacovigilance outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmacovigilance outsourcing refers to the practice of engaging external service providers to perform pharmacovigilance activities on behalf of pharmaceutical companies. These activities involve identifying, evaluating, understanding, and preventing adverse effects or any other issues related to drug use.

The primary types of pharmacovigilance outsourcing include adverse drug reaction capture (ADR), case processing, reporting and submission, report publishing, quality checks, risk management, knowledge management, and enabling architecture. Adverse drug reaction capture involves the identification, documentation, and analysis of harmful or unintended responses to medications, helping ensure drug safety and enhance patient care. These outsourcing services are delivered by organizations such as contract research organizations and business process outsourcing companies. The end users of these services include pharmaceutical companies, research organizations, and others.

The pharmacovigilance outsourcing market includes revenues earned by entities by providing services such as pharmacovigilance database management, assessment services, medical information call center services, regulatory consulting and strategy services, pharmacovigilance compliance and auditing, and aggregate reporting and benefit-risk evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.